Rockville, MD – March 12, 2017 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that a scientific manuscript detailing a characterization study of its non-infectious MVM-Mock Virus Particles (MVM-MVP) has been accepted for publication in the scientific journal Applied Biochemistry and Biotechnology (ABAB).
The study, conducted by the FDA, was part of collaboration between MockV Solutions and the FDA’s Center for Drug Evaluation and Research. One of the key discoveries, reported in ABAB, pertained to the physicochemical similarity of MockV’s non-infectious MVM-MVP’s to live-infectious Minute Virus of Mice (MVM). Size, surface charge, and surface hydrophobicity data demonstrated that these critical characteristics for protein separation applications (ex. chromatography and nanofiltration) were similar among the two particle species. “This data implies that MVM-MVP’s may be useful as an accurate surrogate to live MVM during chromatography or nanofiltration based biopharmaceutical process development and characterization experiments”, said MockV Founder and CEO David Cetlin. “MockV’s goal is to provide these BSL-1 compatible particles as part of a commercial kit that would help scientists design robust viral clearance into their biopharmaceutical processes. This vision dovetails with ‘Quality by Design’ principles and aligns nicely with similar products on the market such as Host Cell Protein and residual Protein A Kits.”
A link to the article is provided here: